| | Average fluorescence intensity |
|---|
Treatments | C-33 A | SiHa | HaCaT |
|---|
No treatment | 1256 | 1405 | 1545 |
Secondary antibody | 1197 | 1465 | 1391 |
CisPT | 1503 | 1575 | 1526 |
LED660 | 1318 | 1533 | 1591 |
MB | 1211 | 1401 | 2069 |
MBPDT | 2471** | 2531** | 2842* |
MBPDT + CisPT | 3362** | 3115** | 10547*** |
LED630 | 1376 | 1489 | 1669 |
PG | 1452 | 1414 | 1677 |
PGPDT | 1386 | 1428 | 1695 |
CisPT + PGPDT | 1444 | 1534 | 10547 |
- Cell lines C-33 A, HaCaT and SiHa were submmited to flow cytometry using anti-γH2AX monoclonal antibody after treatments (CisPT [41.6 μM for 6 h]; MB [19.5 μM for 20 min]; LED 660 nm [5.11 J/cm2]; PG [0.5 μM for 2 h]; LED 630 nm [2.76 J/cm2]; MBPDT [19.5 μM MB + 5.11 J/cm2 LED 660 nm]; MBPDT + CisPT [19.5 μM MB + 5.11 J/cm2 LED 660 nm + 1.3 μM CisPT for 6 h]; PGPDT [0.5 μM PG + 2.76 J/cm2 LED 630 nm]; CisPT + PGPDT [1.3 μM CisPT for 6 h + 0.5 μM PG + 2.76 J/cm2 LED 630 nm]). Asterisks indicate the statistical difference relative to non-treated samples. Kruskal-Wallis, with Dunn’s post-hoc (ns: non significative; *p < 0,05; **p < 0,01; ***p < 0,001). CisPT: cisplatin; MB: methylene blue; MBPDT: photodynamic therapy mediated by MB; PG: Photogem; PGPDT: photodynamic therapy mediated by PG
